TScan Therapeutics is significantly reducing its workforce by 75% to reallocate resources. The company is pausing its hematological and autoimmune programs to prioritize preclinical solid tumor initiatives. This strategic shift aims to advance its solid tumor pipeline and seek partnerships for its paused programs. The decision was influenced by insufficient capital for ongoing trials and a recent collaboration termination. These changes are expected to extend the company's financial runway.
Waltham, Massachusetts
https://www.fiercebiotech.com/biotech/tscan-axes-75-workforce-make-room-solid-tumor-programs